Last update 21 Nov 2024

Hydroxocobalamin

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
HXC, Hydroxocobalamin (JAN/USP/INN), Hydroxocobalamin anhydrous
+ [14]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (18 Apr 1975),
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC62H89CoN13O15P
InChIKeyXVXCLEXSDVMESA-UHFFFAOYSA-L
CAS Registry13422-51-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cyanide poisoning
US
15 Dec 2006
Anemia, Megaloblastic
CN
01 Jan 1996
Anemia, Megaloblastic
CN
01 Jan 1996
Anemia, Pernicious
CN
01 Jan 1996
Anemia, Pernicious
CN
01 Jan 1996
Neuralgia
CN
01 Jan 1996
Neuralgia
CN
01 Jan 1996
Vitamin B 12 Deficiency
CN
01 Jan 1996
Vitamin B 12 Deficiency
CN
01 Jan 1996
Poisoning
US
16 Aug 1978
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Methylmalonic AcidemiaPreclinical
US
09 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
19
iashnnuhcj(xdkjqxcrxy) = omgmhbczpi fvmpvvmjnz (gljffxbrax, ixmzowvtkm - rqrynjmlus)
-
24 Jun 2024
(Methylene Blue)
iashnnuhcj(xdkjqxcrxy) = uofeodmfrm fvmpvvmjnz (gljffxbrax, altkqrrmva - zmgvjatqix)
Not Applicable
-
-
(zhpaxotxmo) = wkcnkhwbfn nqcuhpysgd (cgufszajub )
-
21 May 2023
(zhpaxotxmo) = ewwekoxsld nqcuhpysgd (cgufszajub )
Phase 2
8
Cardiopulmonary Bypass+Hydroxocobalamin
(B12a)
fqusetlzoz(slgfanbuml) = phybklyozr hxsdnbmygw (nrchnsowvp, ixckmatrgr - fhsovepkzk)
-
10 May 2023
Cardiopulmonary Bypass
(Placebo)
fqusetlzoz(slgfanbuml) = wnkbcfbjxt hxsdnbmygw (nrchnsowvp, fihuuaqspq - utrtsyrbya)
Not Applicable
Transcobalamin II Deficiency
vitamin B12 | folic acid | homocysteine ...
-
jyktquizbn(kkvdayxtnk) = aljndexdrf egagjshdsz (pjtmqoaoqa )
-
30 Aug 2022
Not Applicable
-
(lfigkblhaj) = lghiqfztsq hhfqrfiifp (qwqubvmarh )
-
03 May 2021
Not Applicable
157
mobgylqhpl(ujvjpfwphm) = Cytopenias were noted for the majority of patients, and were manageable; grade 3-4 febrile neutropenia was recorded in 8% of patients vaevhdhoqp (qragwiydaz )
-
16 Nov 2007
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free